212 related articles for article (PubMed ID: 21796619)
21. The genetic tumor background is an important determinant for heterogeneous MYCN-amplified neuroblastoma.
Bogen D; Brunner C; Walder D; Ziegler A; Abbasi R; Ladenstein RL; Noguera R; Martinsson T; Amann G; Schilling FH; Ussowicz M; Benesch M; Ambros PF; Ambros IM
Int J Cancer; 2016 Jul; 139(1):153-63. PubMed ID: 26910568
[TBL] [Abstract][Full Text] [Related]
22. High-resolution analysis of allelic imbalance in neuroblastoma cell lines by single nucleotide polymorphism arrays.
Carr J; Bown NP; Case MC; Hall AG; Lunec J; Tweddle DA
Cancer Genet Cytogenet; 2007 Jan; 172(2):127-38. PubMed ID: 17213021
[TBL] [Abstract][Full Text] [Related]
23. Genome-wide array CGH analysis of murine neuroblastoma reveals distinct genomic aberrations which parallel those in human tumors.
Hackett CS; Hodgson JG; Law ME; Fridlyand J; Osoegawa K; de Jong PJ; Nowak NJ; Pinkel D; Albertson DG; Jain A; Jenkins R; Gray JW; Weiss WA
Cancer Res; 2003 Sep; 63(17):5266-73. PubMed ID: 14500357
[TBL] [Abstract][Full Text] [Related]
24. Novel risk stratification of patients with neuroblastoma by genomic signature, which is independent of molecular signature.
Tomioka N; Oba S; Ohira M; Misra A; Fridlyand J; Ishii S; Nakamura Y; Isogai E; Hirata T; Yoshida Y; Todo S; Kaneko Y; Albertson DG; Pinkel D; Feuerstein BG; Nakagawara A
Oncogene; 2008 Jan; 27(4):441-9. PubMed ID: 17637744
[TBL] [Abstract][Full Text] [Related]
25. Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification.
Schleiermacher G; Michon J; Huon I; d'Enghien CD; Klijanienko J; Brisse H; Ribeiro A; Mosseri V; Rubie H; Munzer C; Thomas C; Valteau-Couanet D; Auvrignon A; Plantaz D; Delattre O; Couturier J;
Br J Cancer; 2007 Jul; 97(2):238-46. PubMed ID: 17579628
[TBL] [Abstract][Full Text] [Related]
26. Analysis of chromosome breakpoints in neuroblastoma at sub-kilobase resolution using fine-tiling oligonucleotide array CGH.
Selzer RR; Richmond TA; Pofahl NJ; Green RD; Eis PS; Nair P; Brothman AR; Stallings RL
Genes Chromosomes Cancer; 2005 Nov; 44(3):305-19. PubMed ID: 16075461
[TBL] [Abstract][Full Text] [Related]
27. Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas.
Guo C; White PS; Weiss MJ; Hogarty MD; Thompson PM; Stram DO; Gerbing R; Matthay KK; Seeger RC; Brodeur GM; Maris JM
Oncogene; 1999 Sep; 18(35):4948-57. PubMed ID: 10490829
[TBL] [Abstract][Full Text] [Related]
28. The coamplification pattern of the MYCN amplicon is an invariable attribute of most MYCN-amplified human neuroblastomas.
Weber A; Starke S; Bergmann E; Christiansen H
Clin Cancer Res; 2006 Dec; 12(24):7316-21. PubMed ID: 17189403
[TBL] [Abstract][Full Text] [Related]
29. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci.
Pfister S; Remke M; Benner A; Mendrzyk F; Toedt G; Felsberg J; Wittmann A; Devens F; Gerber NU; Joos S; Kulozik A; Reifenberger G; Rutkowski S; Wiestler OD; Radlwimmer B; Scheurlen W; Lichter P; Korshunov A
J Clin Oncol; 2009 Apr; 27(10):1627-36. PubMed ID: 19255330
[TBL] [Abstract][Full Text] [Related]
30. Aberrant copy numbers of ALK gene is a frequent genetic alteration in neuroblastomas.
Subramaniam MM; Piqueras M; Navarro S; Noguera R
Hum Pathol; 2009 Nov; 40(11):1638-42. PubMed ID: 19656550
[TBL] [Abstract][Full Text] [Related]
31. Correlation of modified Shimada classification with MYCN and 1p36 status detected by fluorescence in situ hybridization in neuroblastoma.
Altungoz O; Aygun N; Tumer S; Ozer E; Olgun N; Sakizli M
Cancer Genet Cytogenet; 2007 Jan; 172(2):113-9. PubMed ID: 17213019
[TBL] [Abstract][Full Text] [Related]
32. Deletions in chromosome arms 3p and 11q are new prognostic markers in localized and 4s neuroblastoma.
Spitz R; Hero B; Ernestus K; Berthold F
Clin Cancer Res; 2003 Jan; 9(1):52-8. PubMed ID: 12538451
[TBL] [Abstract][Full Text] [Related]
33. Changes in MYCN expression in human neuroblastoma cell lines following cisplatin treatment may not be related to MYCN copy numbers.
Prochazka P; Hrabeta J; Vicha A; Cipro S; Stejskalova E; Musil Z; Vodicka P; Eckschlager T
Oncol Rep; 2013 Jun; 29(6):2415-21. PubMed ID: 23563570
[TBL] [Abstract][Full Text] [Related]
34. No evidence for the presence of an imprinted neuroblastoma suppressor gene within chromosome sub-band 1p36.3.
Hogarty MD; Winter CL; Liu X; Guo C; White PS; Look AT; Brodeur GM; Maris JM
Cancer Res; 2002 Nov; 62(22):6481-4. PubMed ID: 12438240
[TBL] [Abstract][Full Text] [Related]
35. Use of chromogenic in situ hybridization to identify MYCN gene copy number in neuroblastoma using routine tissue sections.
Thorner PS; Ho M; Chilton-MacNeill S; Zielenska M
Am J Surg Pathol; 2006 May; 30(5):635-42. PubMed ID: 16699319
[TBL] [Abstract][Full Text] [Related]
36. Analysis of genomic imprinting at 1p35-36 in neuroblastoma.
Hogarty MD; Maris JM; White PS; Guo C; Brodeur GM
Med Pediatr Oncol; 2001 Jan; 36(1):52-5. PubMed ID: 11464906
[TBL] [Abstract][Full Text] [Related]
37. Expression of TSLC1, a candidate tumor suppressor gene mapped to chromosome 11q23, is downregulated in unfavorable neuroblastoma without promoter hypermethylation.
Ando K; Ohira M; Ozaki T; Nakagawa A; Akazawa K; Suenaga Y; Nakamura Y; Koda T; Kamijo T; Murakami Y; Nakagawara A
Int J Cancer; 2008 Nov; 123(9):2087-94. PubMed ID: 18726896
[TBL] [Abstract][Full Text] [Related]
38. ID2 expression in neuroblastoma does not correlate to MYCN levels and lacks prognostic value.
Vandesompele J; Edsjö A; De Preter K; Axelson H; Speleman F; Påhlman S
Oncogene; 2003 Jan; 22(3):456-60. PubMed ID: 12545167
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of mir-21, which is up-regulated during MYCN knockdown-mediated differentiation, does not prevent differentiation of neuroblastoma cells.
Buechner J; Henriksen JR; Haug BH; Tømte E; Flaegstad T; Einvik C
Differentiation; 2011 Jan; 81(1):25-34. PubMed ID: 20980091
[TBL] [Abstract][Full Text] [Related]
40. Positional and functional mapping of a neuroblastoma differentiation gene on chromosome 11.
De Preter K; Vandesompele J; Menten B; Carr P; Fiegler H; Edsjö A; Carter NP; Yigit N; Waelput W; Van Roy N; Bader S; Påhlman S; Speleman F
BMC Genomics; 2005 Jul; 6():97. PubMed ID: 16000168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
